 | Up a level |
2021
Tomaszewska, Agnieszka, Jagasia, Madan, Beohou, Eric, van der Werf, Steffie, Blaise, Didier, Kanfer, Edward, Milpied, Noel, Remenyi, Peter, Ciceri, Fabio, Bourhis, Jean H., Chevallier, Patrice, Solano, Carlos, Socie, Gerard, Bruno, Benedetto, Rambaldi, Alessandro, Castagna, Luca 
ORCID: 0000-0002-6239-7387, Kroger, Nicolaus ORCID: 0000-0001-5103-9966, Corradini, Paolo, Afanasyev, Boris, Ladetto, Marco, Niederwieser, Dietger, Scheid, Christof, Sengeloev, Henrik, Kroschinsky, Frank, Yakoub-Agha, Ibrahim, Schoemans, Helene, Koenecke, Christian, Penack, Olaf ORCID: 0000-0003-4876-802X, Peric, Zinaida, Greinix, Hildegard, Duarte, Rafael F. and Basak, Grzegorz W.
(2021).
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies.
Front. Immunol., 11.
LAUSANNE:
FRONTIERS MEDIA SA.
ISSN 1664-3224
2017
Kroschinsky, Frank, Stoelzel, Friedrich, von Bonin, Simone, Beutel, Gernot, Kochanek, Matthias, Kiehl, Michael and Schellongowski, Peter (2017). New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit. Care, 21. LONDON: BMC. ISSN 1364-8535
2014
Hohloch, Karin, Zwick, Carsten, Ziepert, Marita, Hasenclever, Dirk, Kaiser, Ulrich, Engert, Andreas, Hoeffkes, Heinz-Gert, Kroschinsky, Frank, Mesters, Rolf, Feller, Andreas C., Loeffler, Markus, Truemper, Lorenz and Pfreundschuh, Michael (2014). Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. SpringerPlus, 3. CHAM: SPRINGER INTERNATIONAL PUBLISHING AG. ISSN 2193-1801